Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01138371 · ClinicalTrials.gov registry record
Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers
A clinical trial of Familial Hypercholesterolemia, sponsored by Emory University.
- Completed
- Registry status
- 8
- Enrollment target
- 1
- Study location
NCT01138371 is a study of Familial Hypercholesterolemia that has completed, run by Emory University. The registered enrollment target is 8 participants, below the 225-participant average among 7 other Familial Hypercholesterolemia trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01138371, a study of Familial Hypercholesterolemia, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to measure how LDL apheresis affects levels of inflammatory and cholesterol markers in human beings. The investigators will address this question by drawing pre- and post-LDL apheresis blood from patients who are undergoing this procedure. A secondary objective of this study is to learn how specific inflammatory markers behave in our blood in terms of time to rebound back to normal levels. The investigators will address this question by drawing post-LDL apheresis blood at predetermined time intervals.
Conditions Studied
Interventions
- PROCEDURE LDL Apheresis
Study Locations (1)
Georgia
- Emory University Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01138371
The ClinicalTrials.gov registry entry for NCT01138371 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 225-participant average among 7 other Familial Hypercholesterolemia trials with a reported enrollment target (96% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Familial Hypercholesterolemia appearing as the primary indexed condition, and to 1 intervention - of which LDL Apheresis is the first listed.
NCT01138371 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT01138371 about?
NCT01138371 is a clinical study titled "Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers". The primary objective of this study is to measure how LDL apheresis affects levels of inflammatory and cholesterol markers in human beings. The investigators will address this question by drawing pre- and post-LDL apheresis blood from patients who are undergoing this procedure. A secondary objective...
What is the current status of trial NCT01138371?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2011-03. Estimated completion is 2012-03.
What conditions does trial NCT01138371 study?
This clinical trial studies the following conditions: Familial Hypercholesterolemia.
What interventions are being tested in trial NCT01138371?
The interventions under investigation include: LDL Apheresis (PROCEDURE).
Who is sponsoring clinical trial NCT01138371?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01138371 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Familial Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Atlantic Lipid Lowering Treatment Optimization Program
RECRUITING · NA
-
The ORIGIN-FH Study
RECRUITING · NA
-
2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)
RECRUITING · Phase 2
-
Comparing Direct vs Indirect Methods for Cascade Screening
RECRUITING · NA
-
Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.